Profile data is unavailable for this security.
About the company
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
- Revenue in DKK (TTM)36.56m
- Net income in DKK-86.80m
- Incorporated1917
- Employees48.00
- LocationBioporto A/STuborg Havnevej 15, St.HELLERUP 2900DenmarkDNK
- Phone+45 45290000
- Fax+45 45290001
- Websitehttps://bioporto.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ortoma AB | 54.07m | -5.27m | 291.52m | 10.00 | -- | 2.64 | 79.70 | 5.39 | -0.2027 | -0.2027 | 2.08 | 4.45 | 0.4243 | 3.95 | 39.13 | 7,530,537.00 | -4.13 | -9.37 | -4.45 | -10.43 | 41.26 | 158.24 | -9.74 | -78.90 | 3.02 | -- | 0.00 | -- | 28.77 | -- | 46.83 | -- | -0.5751 | -- |
| Mentice AB | 192.27m | -30.33m | 302.41m | 121.00 | -- | 3.43 | -- | 1.57 | -1.68 | -1.68 | 10.52 | 4.48 | 0.9663 | 1.60 | 3.94 | 2,095,328.00 | -15.25 | -6.64 | -31.60 | -11.91 | 90.40 | 84.80 | -15.78 | -8.53 | 0.845 | -30.10 | 0.116 | -- | 6.11 | 14.22 | -553.89 | -- | 32.86 | -- |
| Q linea AB | 7.77m | -127.82m | 326.25m | 83.00 | -- | 1.38 | -- | 41.97 | -35.87 | -35.87 | 1.31 | 17.84 | 0.0429 | 0.4006 | 2.90 | -- | -70.50 | -76.00 | -101.81 | -93.84 | -15.26 | -145.47 | -1,644.30 | -2,820.51 | 10.04 | -30.48 | 0.017 | -- | 369.86 | 114.75 | 15.86 | -- | -34.47 | -- |
| Modulight Oyj | 52.82m | -34.40m | 354.74m | 71.00 | -- | 1.06 | -- | 6.72 | -0.12 | -0.12 | 0.1874 | 1.05 | 0.1341 | -1.01 | 4.54 | -- | -8.73 | -11.40 | -9.39 | -12.14 | 132.06 | 125.90 | -65.10 | -126.56 | 3.79 | -- | 0.0588 | -- | 72.63 | -6.82 | 28.59 | -- | 15.83 | -- |
| Bactiguard Holding AB | 160.24m | -5.49m | 378.36m | 153.00 | -- | 1.94 | 13.77 | 2.36 | -0.2238 | -0.2238 | 6.53 | 8.99 | 0.381 | 3.44 | 6.91 | 1,495,216.00 | -1.31 | -8.02 | -1.86 | -10.13 | 63.78 | 48.56 | -3.43 | -25.10 | 1.38 | -0.3387 | 0.3410 | -- | -12.64 | 4.22 | 73.69 | -- | -17.92 | -- |
| Gentian Diagnostics ASA | 117.36m | 8.81m | 405.07m | 63.00 | 46.70 | 2.97 | 27.23 | 3.45 | 0.8459 | 0.8459 | 11.35 | 13.29 | 0.7231 | 1.56 | 6.36 | -- | 5.43 | -0.0483 | 6.25 | -0.055 | 55.64 | 47.27 | 7.51 | -0.0788 | 3.81 | -- | 0.0866 | -- | 16.07 | 22.75 | -70.73 | -- | 10.72 | -- |
| Optomed Oyj | 127.74m | -49.62m | 428.81m | 111.00 | -- | 2.39 | -- | 3.36 | -0.3374 | -0.3374 | 0.8688 | 1.12 | 0.5363 | 2.87 | 5.07 | 154,009.00 | -20.83 | -17.19 | -25.75 | -20.69 | 63.60 | 64.81 | -38.85 | -34.21 | 2.03 | -8.91 | 0.1014 | -- | 13.67 | 5.61 | -21.83 | -- | 5.30 | -- |
| BioPorto A/S | 36.56m | -86.80m | 448.07m | 48.00 | -- | 11.70 | -- | 12.26 | -0.1973 | -0.1973 | 0.083 | 0.0774 | 0.4132 | 2.55 | 4.69 | 962,131.60 | -98.08 | -65.22 | -133.92 | -88.74 | 63.90 | 64.15 | -237.40 | -222.22 | 1.71 | -- | 0.1916 | -- | 17.07 | 6.36 | -21.15 | -- | -20.56 | -- |
| Nanexa AB | 25.32m | -7.98m | 459.41m | 15.00 | -- | 6.39 | 570.32 | 18.14 | -0.0724 | -0.0724 | 0.2255 | 0.6237 | 0.3144 | 16.22 | 5.23 | 2,409,933.00 | -9.90 | -31.63 | -12.96 | -38.78 | 86.02 | 96.94 | -31.50 | -218.01 | 1.51 | -3.21 | 0.0109 | -- | 48.39 | 72.50 | 54.27 | -- | 3.54 | -- |
| Senzime AB (publ) | 72.86m | -96.26m | 495.55m | 50.00 | -- | 2.32 | -- | 6.80 | -0.9396 | -0.9396 | 0.7073 | 1.94 | 0.2619 | 2.61 | 7.48 | -- | -34.60 | -36.25 | -37.96 | -39.02 | 33.35 | 24.11 | -132.11 | -271.04 | 3.04 | -7.45 | 0.044 | -- | 77.89 | 61.95 | -15.74 | -- | 123.16 | -- |
| OssDsign AB | 126.19m | -35.72m | 501.35m | 32.00 | -- | 2.31 | -- | 3.97 | -0.5493 | -0.5493 | 2.06 | 2.80 | 0.5109 | 0.3672 | 6.95 | 5,629,938.00 | -14.46 | -25.42 | -16.05 | -28.59 | 96.29 | 85.57 | -28.30 | -82.42 | 6.33 | -13.77 | 0.0044 | -- | 34.51 | 48.59 | -2.68 | -- | 24.28 | -- |
| Omda AS | 315.79m | -20.13m | 542.12m | 260.00 | -- | 23.95 | 27.50 | 1.72 | -1.51 | -1.51 | 23.59 | 1.63 | 0.6793 | 26.59 | 21.70 | 1,772,075.00 | -4.33 | -5.14 | -5.39 | -6.63 | 93.69 | 91.09 | -6.37 | -10.32 | 0.6483 | 0.5281 | 0.9359 | -- | 3.45 | 15.80 | -163.95 | -- | -15.57 | -- |
| Nexstim Oyj | 75.20m | -2.11m | 576.72m | 40.00 | -- | 24.18 | 116.28 | 7.67 | -0.042 | -0.042 | 1.47 | 0.4426 | 0.8553 | 0.5613 | 4.66 | 251,616.80 | -2.40 | -12.40 | -4.17 | -20.76 | 94.36 | 95.09 | -2.81 | -16.29 | 1.08 | 0.7835 | 0.6002 | -- | 20.55 | 21.14 | 32.79 | -- | 15.13 | -- |
| Sedana Medical AB (publ) | 140.25m | -41.50m | 611.62m | 122.00 | -- | 0.9694 | -- | 4.36 | -0.5964 | -0.5964 | 2.02 | 9.07 | 0.2029 | 1.38 | 7.18 | 1,641,205.00 | -6.00 | -5.16 | -6.33 | -5.43 | 71.27 | 70.03 | -29.59 | -32.03 | 2.66 | -1.28 | 0.0052 | -- | 12.01 | 7.15 | -455.03 | -- | -5.91 | -- |
| C Rad AB | 309.60m | 7.28m | 613.08m | 110.00 | 85.71 | 2.59 | 42.28 | 1.98 | 0.3104 | 0.3104 | 13.25 | 10.28 | 0.8928 | 4.29 | 2.40 | 4,018,182.00 | 2.10 | 7.01 | 2.99 | 9.81 | 51.95 | 46.99 | 2.35 | 7.12 | 2.77 | 1.55 | 0.0264 | 2.44 | -5.78 | 14.80 | -81.40 | -6.08 | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Bioporto A/S's reporting currency: Danish Krone DKK
0.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management)as of 30 Nov 2025 | 1.21m | 0.25% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 114.42k | 0.02% |
| AL Sydbank A/S (Investment Management)as of 30 Jan 2026 | 98.78k | 0.02% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 73.51k | 0.02% |
More ▼
Data from 31 Dec 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
